C. Krieckaert

Key findings towards optimising adalimumab treatment: the concentration–effect curve

Mieke F. Pouw, C. Krieckaert, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2013 · 208 citations

Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients

Anna Jamnitski, C. Krieckaert, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2011 · 141 citations

Venous and arterial thromboembolic events in adalimumab‐treated patients with antiadalimumab antibodies: A case series and cohort study

L.-A. Korswagen, G. M. Bartelds, C. Krieckaert et al. · Arthritis & Rheumatism · 2011 · 117 citations

Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects

C. Krieckaert, Sandhya Nair, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2013 · 94 citations

Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation

Pauline A. van Schouwenburg, C. Krieckaert, Theo Rispens et al. · Annals of the Rheumatic Diseases · 2013 · 92 citations